Association of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer Disease
Open Access
- 1 March 2019
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 2 (3) , e190213
Abstract
Alzheimer disease (AD) is the most prevalent cause of dementia. It is characterized by an insidious deterioration of cognitive functions and motor skills, with distinctive behavioral and psychological manifestations.1 Recent estimates suggest that 5.7 million people in the United States currently have AD,2 and as the population ages, the prevalence of AD will drastically increase.3Keywords
This publication has 33 references indexed in Scilit:
- The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase InhibitorsCNS Drugs, 2013
- Donepezil and Memantine for Moderate-to-Severe Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Dementia Medications and Risk of Falls, Syncope, and Related Adverse Events: Meta‐Analysis of Randomized Controlled TrialsJournal of the American Geriatrics Society, 2011
- Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based StudyPLOS Medicine, 2009
- Drug‐induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)Pharmacoepidemiology and Drug Safety, 2009
- Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Safety and efficacy of galantamine in subjects with mild cognitive impairmentNeurology, 2008
- Does memantine induce bradycardia? A study in the French PharmacoVigilance DatabasePharmacoepidemiology and Drug Safety, 2008
- Calculate the QT interval in patients taking drugs for dementiaBMJ, 2007
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004